UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000036395
Receipt No. R000041465
Scientific Title Phase I / IIa trial of R-OKY-034F for pancreatic cancer patients
Date of disclosure of the study information 2019/04/03
Last modified on 2020/04/03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase I / IIa, single-institution, open-label study to explore the safety and efficacy of R-OKY-034F in patients with refractory / intolerable and surgically unresectable pancreatic cancer with standard chemotherapy
Acronym Phase I / IIa, single-institution, open-label study to explore the safety and efficacy of R-OKY-034F in patients with refractory / intolerable and surgically unresectable pancreatic cancer with standard chemotherapy
Scientific Title Phase I / IIa trial of R-OKY-034F for pancreatic cancer patients
Scientific Title:Acronym Phase I / IIa trial of R-OKY-034F for pancreatic cancer patients
Region
Japan

Condition
Condition Pancreatic cancer
Classification by specialty
Hepato-biliary-pancreatic medicine
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Determination of dose-limiting toxicity (DLT) of R-OKY-034F by oral administration of R-OKY-034F orally once daily for patients with refractory / intolerable and surgically unresectable pancreatic cancer with standard chemotherapy And estimate the maximum tolerated dose (MTD) and assess safety to determine the recommended dose (RD) for clinical trials after Phase IIb.
Also, preliminary search for effectiveness.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase Phase I,II

Assessment
Primary outcomes <safety>
1) Determination of dose-limiting toxicity (DLT) of R-OKY-034F
2)Determination of the maximum dose (MTD) of R-OKY-034F

<Effectiveness>
1) Calculation of response rate and disease control rate for each dose when R-OKY-034F is administered
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 R-OKY-034F
once a day for 28 days orally
1, 2.5, 5, 10, 15 mg/kg
Post-observation period: 14 days
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria 1) Disease
Patients who have been diagnosed with pancreatic ductal cancer pathologically or histologically

2) Clinical stage of disease
Image diagnosis by contrast-enhanced CT or contrast-enhanced MRI within 14 days prior to registration, "Diagnoses of Pancreatic cancer medical care guidelines 2016 edition: How is the resectability of pancreatic cancer determined?" Patient Patients who are refractory or intolerant of both gemcitabine-based standard chemotherapy and 5-FU-based standard chemotherapy and have no other standard chemotherapy available

3) Age
Patients aged 20 and over and under 80 at the time of enrollment

4) PS: Performance status
Patients with PS 0 to 2

5) Evaluation possibility of lesion
Patients with one or more measurable lesions defined by RECIST criteria

6) Consent
Patients who have obtained informed consent from patients themselves regarding clinical trial participation

7) prognosis
Patients with a prognosis of more than 2 months
Key exclusion criteria 1) Duplicate cancer
Patients with active double cancer. However, we do not exclude duplicate cancers that do not affect safety and efficacy assessment.

2) Items related to complications
* Patients with unstable angina (angina pectoris onset or attack worsening within 3 weeks before enrollment), or patients with a history of myocardial infarction within 6 months
* Patients with QtcE prolongation of 450 ms or more
* Patients with interstitial lung disease or patients with previous history
* Patients with high degree of disability due to respiratory disease (interstitial lung disease, radiation lung injury etc.) (grade 3 or higher on the modified MRC scale)
* Patients with high physical activity restriction due to heart failure (NYHA class III or higher)
* Patients with intestinal paralysis, intestinal obstruction or severe diarrhea
* Patients who have the following abnormal values for kidney function, liver function and bone marrow function at screening test
- Moderate or higher renal dysfunction with GFR estimate less than 45 ml / min / 1.73 m2
- Moderate or more liver dysfunction, with either AST or ALT> 100 IU / L
- Leukocytes: less than 3,000 / microL
- Neutrophils: less than 1,500 /microL
- Platelet: less than 75,000 / microL
- Hemoglobin: less than 8.0 g / dL
- Total bilirubin: 2.5 mg / dL or more
* Patients weighing less than 40 kg
* Pregnant women
* Breastfeeding women (It is not this limitation if it is possible to refrain from breastfeeding for 14 days after the final oral administration from the study drug oral administration start date)
* Patients who are complicated by psychosis or psychiatric symptoms and judged as difficult to participate in clinical trials

3) Other
* Women and men who can not agree to the practice of highly effective contraception
* Patients who the investigator or subinvestigator judged as inappropriate for trial entry
Target sample size 30

Research contact person
Name of lead principal investigator
1st name Tetsuo
Middle name
Last name Takehara
Organization Osaka University
Division name Department of Gastroenterology and Hepatology
Zip code 565-0871
Address 2-15 Yamadaoka, Suita, Osaka
TEL 06-6879-5111
Email lat1.office@dmi.med.osaka-u.ac.jp

Public contact
Name of contact person
1st name Hideaki
Middle name
Last name Harada
Organization Osaka University
Division name Department of Medical Innovation
Zip code 565-0871
Address 2-2 Yamadaoka, Suita, Osaka
TEL 06-6210-8289
Homepage URL
Email lat1.office@dmi.med.osaka-u.ac.jp

Sponsor
Institute Osaka University Hospital
Institute
Department

Funding Source
Organization AMED
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Institutional Review Board of Osaka University Hospital
Address 2-15 Yamadaoka, Suita, Osaka
Tel 06-6210-8290
Email jim-chiken@hp-crc.med.osaka-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2019 Year 04 Month 03 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2018 Year 09 Month 19 Day
Date of IRB
2018 Year 12 Month 04 Day
Anticipated trial start date
2019 Year 03 Month 20 Day
Last follow-up date
2021 Year 12 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 04 Month 03 Day
Last modified on
2020 Year 04 Month 03 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041465

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.